Speaker - J. Scott Ballenger

 J. Scott  Ballenger  Thumbnail


Scott Ballenger is a partner in the Washington, D.C. office of Latham & Watkins. Prior to joining Latham, Mr. Ballenger served from 1996-1997 as a law clerk to the Hon. J. Clifford Wallace of the United States Court of Appeals for the Ninth Circuit, and during the October 1997 Term as a law clerk to the Hon. Antonin Scalia, Associate Justice of the United States Supreme Court. He then served as Senior Counsel to Assistant Attorney General Joel Klein in the Antitrust Division of the Department of Justice, where he worked on David Boies's trial staff and briefing team for the Division's landmark monopolization case United States v. Microsoft. Since joining Latham in 1999, Mr. Ballenger has focused on appellate and Supreme Court litigation, with an emphasis on constitutional law. He has been the principal author of the merits briefs in five Supreme Court cases - including the winning briefs for the University of Michigan Law School in its landmark affirmative action case Grutter v. Bollinger, 539 U.S. 306 (2003), and for Arthur Andersen in its successful effort to get its conviction for obstruction of justice overturned, Arthur Andersen LLP v. United States, 544 U.S. 696 (2005). Mr. Ballenger has also drafted dozens of amicus curiae briefs, petitions for certiorari, or briefs in opposition to certiorari in the Supreme Court, and many other briefs in the lower federal courts. In a groundbreaking lawsuit against the FDA, Abigail Alliance v. von Eschenbach, 445 F.3d 470 (2006), Mr. Ballenger recently convinced the D.C. Circuit to recognize a new constitutional right of access to experimental drugs for terminally ill patients. He has also extended his United States v. Microsoft experience with complex trial litigation by working on several trial teams in both state and federal court, including Latham's successful defense of Oracle Corporation against the Justice Department, in U.S. v. Oracle Corp., 2004 WL 2006847 (N.D.Ca. 2004).

1 Program

Access to Unproven Therapies: A Debate

09.25.07 | 01:37:32 min | 0 comments